(Total Views: 792)
Posted On: 11/20/2020 12:45:14 AM
Post# of 148902
Re: Evil Rabbit #66020
The primary objective of this phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromal cell (MSC) remestemcel-L plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2.
Primary Outcome Measures :
Number of all-cause mortality [Time Frame: 30 days]
Number of all-cause mortality within 30 days of randomization.
"I think the caveat was that our trial has mortality as the primary endpoint."
Read More: https://investorshangout.com/post/newpost/605...z6eJLlPv5I
Primary Outcome Measures :
Number of all-cause mortality [Time Frame: 30 days]
Number of all-cause mortality within 30 days of randomization.
"I think the caveat was that our trial has mortality as the primary endpoint."
Read More: https://investorshangout.com/post/newpost/605...z6eJLlPv5I
(0)
(0)Scroll down for more posts ▼
